News

I am writing with regards to the Opinion piece titled, “Our Drug Supply Is Sick. How Can We Fix It?” (Sept. 18, 2021). As the writer clearly highlights, the U.S. generic pharmaceutical industry is facing a crisis. Our company, Nexus Pharmaceuticals, Inc., is leading...

Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.

On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin. Wisconsin Governor Tony Evers and U.S. Representative Bryan Steil (WI-01) attended the Project Tomorrow Grand Opening event.

Industry Partnership on EMERPHED™ (Ephedrine Sulfate) Study Bolsters Opportunity for Research and Education | Comparison of EMERPHED™ (Ephedrine Sulfate) Injection with Current Concentrated Ephedrine Products in Simulated Clinical Settings

Nexus is proud to partner with the University of Wisconsin-Parkside and Parkside Athletics in support of their #RangerVision2020 campaign to secure a brighter future for student-athletes, the Parkside Athletics program, and the Wisconsin community.

Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.

Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin.

Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic.

Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers magnified by the Covid-19 pandemic.

Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE).

Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for a second consecutive year.

Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work. Ninety percent of Nexus employees saying the company is a great place to work.

In light of the recent global outbreak of COVID-19 (Novel Coronavirus), Nexus Pharmaceuticals would like to take the opportunity to provide its partners reassurance on Nexus Pharmaceuticals products’ sourcing and manufacturing.

Nexus Pharmaceuticals is pleased to announce the company has ranked #574 in Inc. 5000’s Fastest-Growing Private Companies in America in 2019.

Nexus Pharmaceuticals Inc., a woman-owned, privately held, US-based healthcare company, announced today an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading sterile injectable manufacturing facility.